Capricor Therapeutics shareholders who purchased between December 17, 2025 and July 26, 2026 retain specific rights under federal securities law, including the ability to seek recovery of losses tied to an alleged $15.08 per-share decline following FDA briefing documents on the HOPE-3 trial.
NEW YORK, Aug. 17, 2026 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) that a securities class action has been filed on behalf of shareholders who purchased securities between December 17, 2025 and July 26, 2026. Submit your information. You may also contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.
CAPR fell from $19.70 on July 24, 2026, to $4.19, a decline of approximately 78.7%, with an aggregate corrective-disclosure loss of $15.08 per share. Shares dropped $12.70 (64%) on July 27, 2026 and a further $2.38 (36%) on July 30, 2026. Lead plaintiff applications must be submitted by September 28, 2026.
What Rights Class Members Hold Right Now
Investors do not need to take action before the deadline to remain eligible as absent class members. The action alleges that Capricor did not disclose that it adopted changes to the pre-specified statistical analysis plan for the Phase 3 HOPE-3 trial without FDA agreement, and that the final SAP (v. 3.0) was dated one day before data unblinding. Plaintiffs contend that FDA subsequently characterized the resulting analyses as “post-hoc and exploratory.”
Rights Available to CAPR Purchasers
- The right to seek appointment as lead plaintiff, which gives direct oversight of the litigation, by applying before the court’s deadline
- The right to remain an absent class member and participate in any recovery without filing anything now
- The right to recover regardless of whether shares were sold before or after the July 27, 2026 disclosure
- The right to a free, no-obligation review of trading records at no upfront cost
- The right to select counsel of the investor’s own choosing
- The right to decline participation and pursue individual claims separately
“The timeline raises important questions about when certain risks were known internally versus when they were disclosed to the investing public. Investors who purchased CAPR during the Class Period should understand that their rights are preserved whether or not they seek a lead plaintiff role.” — Joseph E. Levi, Esq.
Why the Advisory Committee Vote Matters to Class Members
The action alleges that the July 29, 2026 advisory committee, voting 9-3, concluded that available evidence does not support the efficacy of deramiocel for DMD-associated cardiomyopathy. Plaintiffs contend this outcome corrected prior alleged misstatements regarding the strength of the HOPE-3 data ahead of the August 22, 2026 PDUFA target action date.
Act now. Click here to learn more
or call (212) 363-7500.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
Frequently Asked Questions About the CAPR Lawsuit
Q: Who is eligible to join the CAPR investor lawsuit? A: Investors who purchased CAPR stock or securities between December 17, 2025 and July 26, 2026 and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses — not on whether you still hold the shares.
Q: What is the CAPR lead plaintiff deadline? A: The deadline to apply for lead plaintiff appointment is September 28, 2026. This deadline applies only to investors seeking to serve as lead plaintiff. Class members who do not apply may still participate in any recovery without taking action before this date.
Q: Who are the defendants named in the CAPR lawsuit? A: The complaint names Capricor Therapeutics, Inc. and individual defendants including senior executives who signed SEC filings, made public statements, or certified financial disclosures under Sarbanes-Oxley.
Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.
Q: What do CAPR investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [email protected] or (212) 363-7500. No immediate action is required to remain eligible as an absent class member.
Q: What if I already sold my CAPR shares — can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought during the Class Period and sold at a loss may still be eligible to participate.
Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. If there is a settlement or recovery, eligible class members generally submit a claim form to seek their portion.
Q: What if I missed the lead plaintiff deadline? A: The deadline applies only to investors seeking lead plaintiff appointment. Class members who miss it may still be able to participate in any potential settlement or recovery.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
